Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 28

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 28
---

“Better health for people, brighter future for the world.”

#### Vision
Our vision is to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet.

#### Values: Takeda-ism
We are guided by our values of Takeda-ism, which incorporate Integrity, Fairness, Honesty and Perseverance, with Integrity at the core. They are brought to life through actions based on Patient-Trust-Reputation-Business, in that order.

#### Imperatives
We honor our responsibility to patients, colleagues and other stakeholders as well as the communities where we operate. Our imperatives help us realize our vision and purpose.

Patient

• We responsibly translate science into highly innovative, life-transforming medicines and vaccines, and accelerate access to improve lives worldwide.

People

• We create an exceptional people experience.

Planet

• We protect our planet.

Unleash the Power of Data and Digital

• We strive to transform Takeda into the most trusted, data-driven, outcomes-based biopharmaceutical company.

<div align='center'>15</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Fiscal Year

Ended March 31, 2025 (Consolidated)

(2) Business Environment, Mid- to Long-Term Business Strategy and Issues to Be Addressed

### Business Environment
The current geopolitical environment is characterized by increasing tensions and growing fragmentation around the world. These shifts are accompanied by a rise in protectionism and trade disputes, which are putting pressure on international commerce, challenging supply chains, and introducing a sense of unpredictability to the outlook for the global economy. Takeda’s value chain is centered in the U.S., Europe, Japan and Singapore, helping reduce our exposure to trade tensions, especially between the U.S. and China. We advocate for health care products to be excluded from trade barriers that will inevitably impact patients.

The most significant challenge currently faced by the biopharmaceutical industry is the gap in health care funding relative to growing demand. This translates into significant pricing pressure and even the capping of market growth in the EU and Japan.

In the U.S., the Inflation Reduction Act, while offering some positives for Medicare patients such as greater predictability in out-of-pocket prescription expenses, introduces an unprecedented government-led price negotiation system for medicines that could potentially result in declines in investment in research and development (R&D).

At Takeda we continue to accelerate the